Tiziana life sciences to pursue development of intranasal foralumab for the treatment of long covid

New york, april 13, 2023 (globe newswire) -- tiziana life sciences ltd. (nasdaq: tlsa) (“tiziana” or the “company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced it plans to investigate intranasal foralumab for the treatment of long covid. the work is supported by foralumab's well-established role in de-activating microglia cells, a key component in the pathogenesis of this disease.
TLSA Ratings Summary
TLSA Quant Ranking